Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor.

Neurologic impairment in HIV-1-associated dementia (HAD) and other neuroinflammatory diseases correlates with injury to dendrites and synapses, but how such injury occurs is not known. We hypothesized that neuroinflammation makes dendrites susceptible to excitotoxic injury following synaptic activity. We report that platelet-activating factor, an inflammatory phospholipid that mediates synaptic plasticity and neurotoxicity and is dramatically elevated in the brain during HAD, promotes dendrite injury following elevated synaptic activity and can replicate HIV-1-associated dendritic pathology. In hippocampal slices exposed to a stable platelet-activating factor analogue, tetanic stimulation that normally induces long-term synaptic potentiation instead promoted development of calcium- and caspase-dependent dendritic beading. Chemical preconditioning with diazoxide, a mitochondrial ATP-sensitive potassium channel agonist, prevented dendritic beading and restored long-term potentiation. In contrast to models invoking excessive glutamate release, these results suggest that physiologic synaptic activity may trigger excitotoxic dendritic injury during chronic neuroinflammation. Furthermore, preconditioning may represent a novel therapeutic strategy for preventing excitotoxic injury while preserving physiologic plasticity.

[1]  S. Swindells,et al.  Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin , 1994, Journal of virology.

[2]  D. Busija,et al.  Diazoxide prevents mitochondrial swelling and Ca2+ accumulation in CA1 pyramidal cells after cerebral ischemia in newborn pigs , 2004, Brain Research.

[3]  Kunio Kato,et al.  Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation , 1994, Nature.

[4]  D. Busija,et al.  Diazoxide preconditioning protects against neuronal cell death by attenuation of oxidative stress upon glutamate stimulation , 2004, Journal of neuroscience research.

[5]  M. Goldberg,et al.  Dendritic Spines Lost during Glutamate Receptor Activation Reemerge at Original Sites of Synaptic Contact , 2001, The Journal of Neuroscience.

[6]  Gary Lynch,et al.  The relationship between extracellular calcium concentrations and the induction of hippocampal long-term potentiation , 1979, Brain Research.

[7]  C. Zorumski,et al.  Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor , 1992, Neuron.

[8]  M. Mattson,et al.  Evidence for Synaptic Apoptosis , 1998, Experimental Neurology.

[9]  L. Schneider,et al.  Memantine for dementia. , 2006, The Cochrane database of systematic reviews.

[10]  M. Cynader,et al.  Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis. , 2003, The American journal of pathology.

[11]  N. Bazan,et al.  Recombinant plasma‐type platelet‐activating factor acetylhydrolase attenuates NMDA‐induced hippocampal neuronal apoptosis , 1998, Journal of neuroscience research.

[12]  B. Vanwinkle,et al.  Diazoxide-mediated Preconditioning against Apoptosis Involves Activation of cAMP-response Element-binding Protein (CREB) and NFκB* , 2004, Journal of Biological Chemistry.

[13]  E. Masliah,et al.  Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis , 2002, Neurology.

[14]  D. Giulian,et al.  Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1 , 1990, Science.

[15]  S. Perry,et al.  Antioxidants are required during the early critical period, but not later, for neuronal survival , 2004, Journal of neuroscience research.

[16]  E. Masliah,et al.  Dendritic injury is a pathological substrate for human immunodeficiency virus—related cognitive disorders , 1997, Annals of neurology.

[17]  J. Swann,et al.  A role for sodium and chloride in kainic acid-induced beading of inhibitory interneuron dendrites , 2000, Neuroscience.

[18]  Jean-Luc Puel,et al.  Excitotoxicity and repair of cochlear synapses after noise‐trauma induced hearing loss , 1998, Neuroreport.

[19]  Y. Hannun,et al.  Platelet-activating Factor Receptor Activation , 1998, The Journal of Biological Chemistry.

[20]  H. Pernerstorfer-Schön,et al.  Highly active antiretroviral therapy for patients with AIDS dementia complex: effect on MR imaging findings and clinical course. , 2000, AJNR. American journal of neuroradiology.

[21]  H. Gendelman,et al.  Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease , 1992, The Journal of experimental medicine.

[22]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[23]  M. Goldberg,et al.  Distinct Roles for Sodium, Chloride, and Calcium in Excitotoxic Dendritic Injury and Recovery , 1998, Experimental Neurology.

[24]  M. Packard,et al.  Effects of Posttraining Intrahippocampal Injections of Platelet-Activating Factor and PAF Antagonists on Memory , 1998, Neurobiology of Learning and Memory.

[25]  Chrétien,et al.  Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage , 1999, Neuropathology and applied neurobiology.

[26]  D. Bredt,et al.  Targeted disruption of PSD-93 gene reduces platelet-activating factor-induced neurotoxicity in cultured cortical neurons , 2004, Experimental Neurology.

[27]  C. Achim,et al.  Selective Neuronal Vulnerability in HIV Encephalitis , 1992, Journal of neuropathology and experimental neurology.

[28]  G. Collingridge,et al.  An electrophysiological characterisation of long-term potentiation in cultured dissociated hippocampal neurones , 2001, Neuropharmacology.

[29]  D. Busija,et al.  Diazoxide induces delayed pre‐conditioning in cultured rat cortical neurons , 2003, Journal of neurochemistry.

[30]  F. Bari,et al.  Diazoxide and dimethyl sulphoxide prevent cerebral hypoperfusion-related learning dysfunction and brain damage after carotid artery occlusion , 2004, Brain Research.

[31]  T. Manabe,et al.  Platelet‐activating factor receptor is not required for long‐term potentiation in the hippocampal CA1 region , 1999, The European journal of neuroscience.

[32]  T. Tuñón,et al.  Neuronal alterations in patients with dementia: a Golgi study on biopsy samples , 1990, Neuroscience Letters.

[33]  E. Masliah,et al.  Synaptic and neuritic alterations during the progression of Alzheimer's disease , 1994, Neuroscience Letters.

[34]  T. Yue,et al.  Evidence for platelet-activating factor as a novel mediator in experimental stroke in rabbits. , 1990, Stroke.

[35]  E. Masliah,et al.  Cortical dendritic pathology in human immunodeficiency virus encephalitis. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[36]  D. Hanahan,et al.  Production and effects of platelet-activating factor in the rat brain. , 1988, Biochimica et biophysica acta.

[37]  H. Gendelman,et al.  Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. , 1998, The Journal of infectious diseases.

[38]  Takao Shimizu,et al.  Interaction between neurone and microglia mediated by platelet‐activating factor , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[39]  P. Lantos,et al.  Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia , 1994, Acta Neuropathologica.

[40]  Carl W. Cotman,et al.  β-Amyloid Induces Local Neurite Degeneration in Cultured Hippocampal Neurons: Evidence for Neuritic Apoptosis , 1998, Neurobiology of Disease.

[41]  Takao Shimizu,et al.  Predominant Expression of Platelet-Activating Factor Receptor in the Rat Brain Microglia , 1996, The Journal of Neuroscience.

[42]  Y. Tao,et al.  Involvement of the NMDA receptor/nitric oxide signal pathway in platelet-activating factor-induced neurotoxicity , 2004, Neuroreport.

[43]  D. Holtzman,et al.  Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. , 2005, The Journal of clinical investigation.

[44]  S. Warach,et al.  Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  I. Izquierdo,et al.  Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance task. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Keizo Inoue,et al.  Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer , 1997, Nature.

[47]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[48]  M. Lazdunski,et al.  Disruption of Mitochondrial Respiration Inhibits Volume-Regulated Anion Channels and Provokes Neuronal Cell Swelling , 1998, The Journal of Neuroscience.

[49]  N. Nishiyama,et al.  Rapid and reversible changes in dendrite morphology and synaptic efficacy following NMDA receptor activation: implication for a cellular defense against excitotoxicity. , 2001, Journal of cell science.

[50]  I. Kudryashov,et al.  Caspase activity is essential for long‐term potentiation , 2003, Journal of neuroscience research.

[51]  Michael C. Bateman,et al.  Rapid Alterations in Dendrite Morphology during Sublethal Hypoxia or Glutamate Receptor Activation , 1996, Neurobiology of Disease.

[52]  C. Masters,et al.  Sublethal Concentrations of Prion Peptide PrP106–126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons , 2001, Neurobiology of Disease.